For routine prophylaxis in patients 12 years and older with hemophilia A or B without inhibitors

NOW APPROVED

INTRODUCING HYMPAVZI—a once-weekly subcutaneous prophylactic treatment that comes in a fixed-dose,* prefilled pen

Not actual size.

Sign up for more information

What sets HYMPAVZI apart?

Prefilled pen. Fixed dose.* Once weekly

HYMPAVZI comes ready to use; there’s no measuring. No mixing. No reconstitution.

Innovative approach to hemophilia treatment

HYMPAVZI works to help achieve hemostasis (how your body stops or prevents bleeding) through rebalancing.

Delivered bleed protection

HYMPAVZI was shown to help protect patients from bleeds.

*Your first dose (loading dose) of HYMPAVZI is 300 mg (two 150 mg injections). Then you will inject a weekly (maintenance) dose consisting of 1 or 2 injections as prescribed by your healthcare provider. If more than one injection is required to deliver a complete dose, administer each injection at a different injection site.

In the phase 3 clinical trial, the primary objective of the study was to measure the Annualized Bleed Rate (ABR) vs on-demand factor-based treatment and vs factor-based prophylaxis after 12 months on HYMPAVZI. 92% reduction in treated bleeds on HYMPAVZI compared to on-demand factor-based treatment (3.18 ABR vs 38.00 ABR). 35% reduction in treated bleeds on HYMPAVZI compared to routine prophylaxis treatment (5.08 ABR vs 7.85 ABR).

ABR = annualized bleed rate

Receive updates and helpful educational tools for HYMPAVZI

Sign up for more information

Register now

Education and support you can count on

Pfizer Patient Affairs Liaisons (PALs) are available to help you access the educational support and information you need.

Start here

Pfizer PALs are not measured or awarded based on sales performance, nor will they ask you to switch products.

Come see us at the HOPE Conference in Orlando, FL!

Nov. 7th-9th | Booth #303